365 related articles for article (PubMed ID: 37108451)
1. The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers.
Tang H; Kulkarni S; Peters C; Eddison J; Al-Ani M; Madhusudan S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108451
[TBL] [Abstract][Full Text] [Related]
2. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
3. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
Ciccone MA; Adams CL; Bowen C; Thakur T; Ricker C; Culver JO; Maoz A; Melas M; Idos GE; Jeyasekharan AD; Matsuo K; Roman LD; Gruber SB; McDonnell KJ
Gynecol Oncol; 2020 Dec; 159(3):869-876. PubMed ID: 33032822
[TBL] [Abstract][Full Text] [Related]
5. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
6. Targeting DNA damage repair precision medicine strategies in cancer.
Brownlie J; Kulkarni S; Algethami M; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Curr Opin Pharmacol; 2023 Jun; 70():102381. PubMed ID: 37148685
[TBL] [Abstract][Full Text] [Related]
7. Evolving DNA repair synthetic lethality targets in cancer.
Kulkarni S; Brownlie J; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Biosci Rep; 2022 Dec; 42(12):. PubMed ID: 36420962
[TBL] [Abstract][Full Text] [Related]
8. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
9. [PARP INHIBITORS FOR ADJUVANT TREATMENT FOR OVARIAN CANCER].
Marom I; Lavie O; Ostrovsky L; Kugelman N; Schmidt M; Segev Y
Harefuah; 2020 Mar; 159(3):175-180. PubMed ID: 32186787
[TBL] [Abstract][Full Text] [Related]
10. Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
Vanacker H; Romeo C; Ray-Coquard I
Curr Opin Oncol; 2019 Sep; 31(5):394-403. PubMed ID: 31335830
[TBL] [Abstract][Full Text] [Related]
11. PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
Ali R; Alabdullah M; Alblihy A; Miligy I; Mesquita KA; Chan SY; Moseley P; Rakha EA; Madhusudan S
Cancer Lett; 2020 Jan; 469():124-133. PubMed ID: 31669203
[TBL] [Abstract][Full Text] [Related]
12. Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
Washington C; Gunderson CC; Moore KN
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):4-11. PubMed ID: 30451713
[TBL] [Abstract][Full Text] [Related]
13. Towards Personalized Management of Ovarian Cancer.
Algethami M; Kulkarni S; Sadiq MT; Tang HKC; Brownlie J; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Cancer Manag Res; 2022; 14():3469-3483. PubMed ID: 36545222
[TBL] [Abstract][Full Text] [Related]
14. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
15. Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
Li J; Li Q; Zhang L; Zhang S; Dai Y
Biomed Pharmacother; 2023 Jan; 157():114028. PubMed ID: 36410122
[TBL] [Abstract][Full Text] [Related]
16. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
17. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
18. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.
Revythis A; Limbu A; Mikropoulos C; Ghose A; Sanchez E; Sheriff M; Boussios S
Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886427
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.
Moore KN; Pothuri B
Cancer J; 2021 Nov-Dec 01; 27(6):432-440. PubMed ID: 34904806
[TBL] [Abstract][Full Text] [Related]
20. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
